IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Results from a groundbreaking clinical trial could soon change the way certain types of cancers are treated. A study ...

Immunotherapy let some cancer patients with mismatch repair deficient tumors completely avoid surgery, chemo and radiation, a ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...

Vitamin D supplements may help decrease the risk of colorectal cancer and improve survival for people with colorectal cancer, ...

BOSTON, MA, USA I April 25, 2025 I Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful ...

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation or chemotherapy.

Researchers with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U ...

Marisa Peters, a 43-year-old mother-of-three and advocacy worker from California, has revealed the 'unglamorous' stage three ...